Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.

van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.

PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.

2.

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.

van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E.

J Clin Pathol. 2009 Oct;62(10):926-30. doi: 10.1136/jcp.2009.065524. Epub 2009 Jun 18.

PMID:
19541683
3.

High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.

van der Groep P, Bouter A, Menko FH, van der Wall E, van Diest PJ.

Breast Cancer Res Treat. 2008 Oct;111(3):475-80. Epub 2007 Nov 21.

PMID:
18030615
4.

Ductal carcinoma in situ in BRCA mutation carriers.

Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL.

J Clin Oncol. 2007 Feb 20;25(6):642-7. Epub 2007 Jan 8.

PMID:
17210933
5.

miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.

Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.

Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.

6.

Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.

Chen CL, Chu JS, Su WC, Huang SC, Lee WY.

Virchows Arch. 2010 Jul;457(1):53-61. doi: 10.1007/s00428-010-0938-0. Epub 2010 Jun 5.

PMID:
20526721
7.

CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.

Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J.

Neoplasma. 2010;57(4):325-32.

PMID:
20429623
8.

VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.

Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A.

PLoS One. 2013;8(1):e53070. doi: 10.1371/journal.pone.0053070. Epub 2013 Jan 11.

9.

Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL; kConFab Investigators.

Genes Chromosomes Cancer. 2004 Mar;39(3):236-48.

PMID:
14732925
10.

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.

Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.

J Transl Med. 2015 Oct 24;13:335. doi: 10.1186/s12967-015-0698-3.

11.

Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.

Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25. Erratum in: Cancer. 2014 Mar 15;120(6):927.

12.

High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT.

Cancer Prev Res (Phila). 2009 Feb;2(2):122-7. doi: 10.1158/1940-6207.CAPR-08-0050. Epub 2009 Jan 27.

13.

Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.

Zikan M, Bohm J, Pavlista D, Cibula D.

Clin Transl Oncol. 2011 Sep;13(9):652-5. doi: 10.1007/s12094-011-0710-1.

PMID:
21865136
14.

The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers.

Mazzola E, Cheng SC, Parmigiani G.

Breast Cancer Res Treat. 2013 Jan;137(1):315-8. doi: 10.1007/s10549-012-2345-5. Epub 2012 Nov 27.

15.

A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.

Nomizu T, Matsuzaki M, Katagata N, Kobayashi Y, Sakuma T, Monma T, Saito M, Watanabe F, Midorikawa S, Yamaguchi Y.

Breast Cancer. 2015 Sep;22(5):557-61. doi: 10.1007/s12282-012-0432-4. Epub 2012 Dec 15.

PMID:
23242612
16.

BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.

Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):467-74.

17.

Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.

Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK.

Ann Surg Oncol. 2014 Oct;21(11):3466-72. doi: 10.1245/s10434-014-3747-x. Epub 2014 May 6.

18.

Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ.

Cancer Res. 1999 Apr 15;59(8):2011-7.

20.

Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?

Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S, Jungbluth AA.

Cancer Immunol Immunother. 2011 Jul;60(7):999-1007. doi: 10.1007/s00262-011-1005-7. Epub 2011 Apr 5.

Supplemental Content

Support Center